Established in 1989, Akers Biosciences is a publicly traded company that designs, manufactures and supplies a range of point-of-care screening and testing products for the health care industry. It specializes in the development of various diagnostics and related technologies for patients and health care providers worldwide. The company has developed a range of technologies for the diagnosis of chlamydia, cytomegalovirus, dengue fever, gonorrhea, infectious mononucleosis, malaria, syphilis, rheumatoid arthritis, hepatitis C, and lyme and chagas diseases. Its products are available under the BreathScan and HealthTEST brands. The company additionally provides the PIFA Heparin/PF4 Rapid Assay, which is a single-use patient test that determines the antibody status in minutes versus hours. It also offers diagnostic technologies under the minDNA and Biosniffer brands. The company has partnerships with several aid organizations, government agencies, physicians, and biotechnology and pharmaceutical companies. Akers Biosciences maintains a presence in the United Kingdom.
Partial Data by Infogroup (c) 2024. All rights reserved.